Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

Inclusion Criteria: * Histologically proven NSCLC diagnosis * Life expectancy over four weeks * absolute neutrophil count ≥ 2.0X109/L, Pt ≥ 100X109/L, hemoglobin ≥ 90g/l * With normal hepatic function(AST, ALT \< 2.5 x upper limit of normal , and Total bilirubin ≤ upper limit of normal) * Suitable for EGFR-TKIs treatment and expectant duration over four weeks * No specific therapies received within 4 weeks prior to enrollment which may induce similar skin reaction,such as Cetuximab, Sorafenib, Avastin. * With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events \[NCI-CTC\] grade ≥ 3) * No other concomitant therapy referred to the face skin during the study * Signed and dated informed consent Exclusion Criteria: * Performance status ≥ 3(ECOG) * Pregnant or breast-feeding patients * The lesion counts can't be evaluated due to concomitant diseases or other conditions * Not suitable for EGFR-TKIs treatment